Monash IVF Group Ltd.’s stock is under pressure as the profit falls by 27.9% in FY 18

Monash IVF Group Ltd.’s stock is under pressure as the profit falls by 27.9% in FY 18

Profit falls by 27.9% in FY 18: Monash IVF Group Ltd.’s (ASX: MVF) stock fell 6.6% on August 27, 2018 (3:20 PM AEST) after the company for FY 18 reported 27.9% fall in the profit to $21 million, 22.2% fall in EBITDA and 2.9% fall in the revenue to $151 million. The company is into a fertility research and treatment, where the company researches and develops reproduction supportive medications.

[optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]

The topline in FY 18 is impacted by a Specialist departure and a decline in the Australian ARS market. The EBITDA Margin for FY 18 declined to 25.3% from 31.6%, due to the leverage impact from volume decline in Victoria, continued investment in the Operations, People, Science & Technology and International business and also due to one-off costs incurred on the back of Fertility Specialist departure in Victoria and restraint legal proceedings, recruitment of key personnel and organisation restructure ($1.2m).

Additionally, 1H19 NPAT is expected to decline by approximately 15% on pcp, as 1H18 includes the one quarter of ARS activity from a departed Specialist. MVF expects to deliver NPAT growth in FY19 on pcp. MVF stock has risen 7.56% in three months as on August 24, 2018 and is trading at a P/E of 11.39x.

Dividend Stocks To Buy

The Income available from dividends remains attractive for many investors.

We take a look at the best yields on the market and assess what they say about a company’s prospect.

One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”

ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.

Click here to get your free report.


The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.

Checkout our Free Dividend Stocks Report

Specially made for income-hungry investors, Invest in growing Franked Dividends an opportunity that should not be missed.

6 Cannabis Stocks under Investor’s Limelight…

Cannabis companies that sell both medicinal weed and recreational pot. Marijuana stocks to look at. Marijuana mergers and acquisitions. Dispensary data analytics. Upcoming marijuana IPO’s Those phrases have become increasingly common as marijuana legalization spreads.

Global spending on legal cannabis is expected to grow 230% to $32 billion in 2020 as compared to $9.5 in 2017, according to Arcview Market Research and BDS Analytics. As of June 29, 2018 the United States Marijuana Index, despite a lot of uncertainty around regulations, has over the past 1 year gained 71.49%, as compared to about 12% gain seen by the S&P 500.

Click here for your FREE Report